Have a feature idea you'd love to see implemented?
Let us know!
KALV KalVista Pharmaceuticals Inc
Price (delayed)
$9.325
Market cap
$402.98M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.58
Enterprise value
$376.12M
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary
Highlights
KalVista Pharmaceuticals's debt has decreased by 27% YoY and by 17% QoQ
KALV's equity is up by 24% year-on-year but it is down by 16% since the previous quarter
KalVista Pharmaceuticals's net income has decreased by 49% YoY and by 12% from the previous quarter
KALV's quick ratio is down by 16% since the previous quarter and by 11% year-on-year
Key stats
What are the main financial stats of KALV
Market
Valuations
Earnings
Shares outstanding
43.22M
Market cap
$402.98M
Enterprise value
$376.12M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.31
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$141.77M
EBITDA
-$140.94M
Free cash flow
-$103.24M
Per share
Balance sheet
Liquidity
EPS
-$3.58
Free cash flow per share
-$2.23
Book value per share
$4.04
Revenue per share
$0
TBVPS
$4.33
Total assets
$200.2M
Total liabilities
$27.4M
Debt
$4.99M
Equity
$172.8M
Working capital
$169.22M
Debt to equity
0.03
Current ratio
8.55
Quick ratio
7.78
Net debt/EBITDA
0.19
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-82.4%
Return on equity
-97.4%
Return on invested capital
-116.8%
Return on capital employed
-79.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KALV stock price
How has the KalVista Pharmaceuticals stock price performed over time
Intraday
4.07%
1 week
-4.85%
1 month
-24.31%
1 year
20.63%
YTD
-23.88%
QTD
-19.47%
Financial performance
How have KalVista Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$155.57M
Net income
-$141.77M
Gross margin
N/A
Net margin
N/A
KalVista Pharmaceuticals's net income has decreased by 49% YoY and by 12% from the previous quarter
KALV's operating income is down by 37% YoY and by 11% QoQ
Growth
What is KalVista Pharmaceuticals's growth rate over time
Valuation
What is KalVista Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.31
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 14% YoY and by 4.1% from the previous quarter
The P/B is 38% lower than the last 4 quarters average of 3.7 and 11% lower than the 5-year quarterly average of 2.6
KALV's equity is up by 24% year-on-year but it is down by 16% since the previous quarter
Efficiency
How efficient is KalVista Pharmaceuticals business performance
KalVista Pharmaceuticals's return on equity has shrunk by 61% YoY and by 6% QoQ
The ROA has shrunk by 54% YoY and by 6% QoQ
KalVista Pharmaceuticals's return on invested capital has decreased by 40% YoY
Dividends
What is KALV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KALV.
Financial health
How did KalVista Pharmaceuticals financials performed over time
The company's total liabilities rose by 30% YoY but it fell by 4.9% QoQ
KALV's total assets is up by 25% YoY but it is down by 15% QoQ
KalVista Pharmaceuticals's debt is 97% lower than its equity
The debt to equity has contracted by 40% YoY
KalVista Pharmaceuticals's debt has decreased by 27% YoY and by 17% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.